Quick Answer
bioAffinity Technologies, Inc. reported Diluted EPS of $8.66 per share (loss) for fiscal year 2025.
bioAffinity Technologies, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$8.66 | +61.5% |
| 2024 | -$22.50 | -2372.5% |
| 2023 | -$0.91 | +49.7% |
| 2022 | -$1.81 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$4.74 | +2.1% | -2688.2% |
| June 30, 2025 | -$0.17 | +10.5% | -6.3% |
| March 31, 2025 | -$0.16 | +20.0% | +96.7% |
| September 30, 2024 | -$4.84 | -1761.5% | -2447.4% |
| June 30, 2024 | -$0.19 | +5.0% | +5.0% |
| March 31, 2024 | -$0.20 | -11.1% | +23.1% |
| September 30, 2023 | -$0.26 | +77.8% | -30.0% |
| June 30, 2023 | -$0.20 | -566.7% | -11.1% |
- bioAffinity Technologies, Inc. showed an increase of +61.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, bioAffinity Technologies, Inc.’s diluted eps has declined by 378.5% (from $1.81 per share (loss) to $8.66 per share (loss)).
- The most recent figure is from bioAffinity Technologies, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: